Confidential Treatment Requested. Confidential portions of this documents have been redacted and separately filed with the Commission. ***** Confidential material redacted and filed separately with the Commission.Research and Licence Agreement • July 14th, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations
We set out below the amendments to the Agreement (as already amended by Amendment No. 1) and to Amendment No. 1 agreed between Yeda Research and Development Co. Ltd. (“Yeda”) and XTL Biopharmaceuticals, Ltd. (“the Corporation”) following discussions between the parties conducted at the Corporation’s request:
AND -Research and Licence Agreement • May 18th, 1999 • Geron Corporation • Pharmaceutical preparations
BETWEEN:Research and Licence Agreement • June 23rd, 2005 • Chemgenex Pharmaceuticals LTD • American depositary receipts
Confidential Treatment Requested. Confidential portions of this document have been redacted and separately filed with the Commission. ***** Confidential material redacted and filed separately with the Commission. January 26, 2003Research and Licence Agreement • July 14th, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations
We set out below the amendments to Amendments No. 1 and No. 2 agreed between Yeda Research and Development Company Ltd. (“Yeda”) and XTL Biopharmaceuticals Ltd. (“the Corporation”) following discussions between the parties conducted at the Corporation’s request (capitalised terms herein having the meanings ascribed thereto in the R&L Agreement, unless otherwise defined herein):
ContractResearch and Licence Agreement • March 30th, 2020 • Cell Source, Inc. • Pharmaceutical preparations
Certain information has been excluded from this exhibit because (i) it is not material and (ii) would be competitively harmful if publicly disclosed.
Confidential Treatment Requested. Confidential portions of this document have been redacted and separately filed with the Commission. ***** Confidential material redacted and filed separately with the Commission.Research and Licence Agreement • August 29th, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations
We set out below the amendments to Amendments No. 1 and No. 2 agreed between Yeda Research and Development Company Ltd. (“Yeda”) and XTL Biopharmaceuticals Ltd. (“the Corporation”) following discussions between the parties conducted at the Corporation’s request (capitalised terms herein having the meanings ascribed thereto in the R&L Agreement, unless otherwise defined herein):
SEVENTH AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this “Amendment”) Effective Date: November 15, 2020 by and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100,...Research and Licence Agreement • April 15th, 2021 • Cell Source, Inc. • Pharmaceutical preparations
WHEREAS Yeda and Cell Source are parties (the “Parties”) to a Research and Licence Agreement dated October 3, 2011, as amended by a First Amendment thereto dated April 8, 2014, a Second Amendment thereto dated November 28, 2016, a Third Amendment thereto dated March 29, 2018, a Fourth Amendment thereto dated March 30, 2018, a Fifth Amendment thereto dated June 30, 2019, and a Sixth Amendment dated December 31, 2019 (together, “the R&L Agreement”); and
